Recent Data from JBCRG-M06/EMERALD in HER2+ Breast Cancer

Opinion
Video

Focusing on HER2+ breast cancer, Erika P. Hamilton, MD, and the Oncology Brothers review data from JBCRG-M06/EMERALD looking at trastuzumab and pertuzumab in combination with eribulin or a taxane in locally advanced or metastatic disease.

Recent Videos
Related Content
Advancing Treatments for ET and CDK4/6 Resistance in HR+ Breast Cancer

Advancing Treatments for ET and CDK4/6 Resistance in HR+ Breast Cancer

Silas Inman
March 10th 2025
Article

New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.

Read More

Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

Jordyn Sava;Aditya Bardia, MD, MPH
February 6th 2025
Podcast

In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan in breast cancer.

Listen

HR+/MP-H2 Breast Cancers Resemble Triple-Negative, Guiding New Therapies

HR+/MP-H2 Breast Cancers Resemble Triple-Negative, Guiding New Therapies

Jordyn Sava
March 3rd 2025
Article

Alejandro Rios Hoyo discussed findings on a subset of hormone receptor–positive, HER2-negative breast cancers classified as MP-H2.

Read More

Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

Jordyn Sava;Sanjay K. Juneja, MD
January 15th 2025
Podcast

In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.

Listen

FDA Expands PATHWAY HER2 (4B5) Test to Include HER2-Ultralow Status

FDA Expands PATHWAY HER2 (4B5) Test to Include HER2-Ultralow Status

Jordyn Sava
February 5th 2025
Article

The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its prior HER2-low indication.

Read More

FDA Considers BLA for Pertuzumab Biosimilar HLX11 in Breast Cancer

FDA Considers BLA for Pertuzumab Biosimilar HLX11 in Breast Cancer

Jordyn Sava
February 5th 2025
Article

FDA reviews biologics license application for HLX11, a biosimilar to pertuzumab, for HER2-positive breast cancer.

Read More